- Home
- ZION vs QGEN Comparison
ZION vs QGEN Comparison
Compare ZION & QGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ZION | QGEN |
|---|---|---|
| Founded | 1873 | 1986 |
| Country | United States | Netherlands |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.4B | 8.7B |
| IPO Year | 2012 | 1998 |
Fundamental Metrics
Financial Performance| Metric | ZION | QGEN |
|---|---|---|
| Price | $71.37 | $42.58 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 18 | 8 |
| Target Price | ★ $65.33 | $45.76 |
| AVG Volume (30 Days) | 1.5M | ★ 2.5M |
| Earning Date | 04-20-2026 | 05-06-2026 |
| Dividend Yield | 2.88% | ★ 7.17% |
| EPS Growth | ★ 21.41 | N/A |
| EPS | ★ 4.61 | N/A |
| Revenue | ★ $662,000,000.00 | N/A |
| Revenue This Year | $8.57 | $8.18 |
| Revenue Next Year | $4.67 | $5.71 |
| P/E Ratio | ★ $15.53 | $24.01 |
| Revenue Growth | ★ 3.60 | N/A |
| 52 Week Low | $46.21 | $32.53 |
| 52 Week High | $73.34 | $57.82 |
Technical Indicators
Market Signals| Indicator | ZION | QGEN |
|---|---|---|
| Relative Strength Index (RSI) | 54.27 | 57.36 |
| Support Level | $67.89 | $39.08 |
| Resistance Level | $71.26 | $44.22 |
| Average True Range (ATR) | 1.21 | 0.88 |
| MACD | -0.01 | -0.07 |
| Stochastic Oscillator | 61.70 | 51.41 |
Price Performance
Historical ComparisonAbout ZION Zions Bancorporation N.A.
Zions Bancorp is a US regional bank with around $90 billion in total assets as of Sept. 30, 2025. Headquartered in Salt Lake City, Utah, Zions' branch network is in the Western and Southwestern United States and includes seven affiliate banks in these markets. The bank has a heavy focus on small and midsize commercial banking.
About QGEN Qiagen N.V.
Qiagen offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins. The company's sales are split almost evenly between applications in life sciences and molecular diagnostics. Qiagen generates nearly 90% of its revenue from consumables with the balance coming from instrumentation and related services. The Americas account for the largest portion of the firm's revenue (52% of 2024 sales), followed by EMEA (33%), and the Asia-Pacific (15%).